pembrolizumab   Click here for help

GtoPdb Ligand ID: 7499

Synonyms: Keytruda® | lambrolizumab | MK-3475
Approved drug Immunopharmacology Ligand
pembrolizumab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Pembrolizumab is the first-in-class, anti-PD-1 antibody to be approved by the US FDA.
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.

Pembrolizumab is the first immuno-oncology therapeutic to be approved for use in cancers of any tissue type, so long as they express a specific genetic biomarker (i.e. high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) tumours). This is an important breakthrough, since up until this point FDA approvals, including earlier approvals for pembrolizumab, had always been restricted to certain tissue-specific cancers.
Click here for help
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 (CD279) Primary target of this compound Hs Antibody Binding ~10.0 pKd - 1
pKd ~10.0 (Kd ~1x10-10 M) [1]
Ligand mentioned in the following text fields